1. Impact of sorafenib on epidural fibrosis: An immunohistochemical study
- Author
-
Omur Gunaldi, Ilhan Yilmaz, Metehan Eseoğlu, Uzay Erdogan, Osman Tanriverdi, Ayca Arslanhan, Huseyin Utku Adilay, Canan Tanik, Tıp Fakültesi, Tanriverdi, Osman, Erdogan, Uzay, Gunaldi, Omur Univ Hlth Sci, Bakirky Prof Dr Mazhar Osman Training & Res Hosp, Dept Neurosurg & Psychiat, Tevfik Saglam Cad 1, TR-34303 Istanbul, Turkey, Tanik, Canan Univ Hlth Sci, Sisli Hamidiye Etfal Training & Res Hosp, Dept Pathol, TR-34303 Istanbul, Turkey, Yilmaz, Ilhan Univ Hlth Sci, Sisli Hamidiye Etfal Training & Res Hosp, Dept Neurosurg, TR-34303 Istanbul, Turkey, Adilay, Huseyin Utku Balikesir Univ, Med Fac, Dept Neurosurg, TR-31300 Balikesir, Turkey, Arslanhan, Ayca Marmara Univ, Inst Neurol Sci, TR-34303 Istanbul, Turkey, Eseoglu, Metehan Medipol Univ, Med Fac, Dept Neurosurg, TR-34303 Istanbul, Turkey, Tanriverdi, O., Department of Neurosurgery and Psychiatry, University of Health Sciences, Bakirky Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Istanbul, 34303, Turkey, Erdogan, U., Department of Neurosurgery and Psychiatry, University of Health Sciences, Bakirky Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Istanbul, 34303, Turkey, Tanik, C., Department of Pathology, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, 34303, Turkey, Yilmaz, I., Department of Neurosurgery, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, 34303, Turkey, Gunaldi, O., Department of Neurosurgery and Psychiatry, University of Health Sciences, Bakirky Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Istanbul, 34303, Turkey, Adilay, H.U., Department of Neurosurgery, Medical Faculty, Balikesir University, Balikesir, 31300, Turkey, Arslanhan, A., Institute of Neurological Science, Marmara University, Istanbul, 34303, Turkey, and Eseoglu, M., Department of Neurosurgery, Medical Faculty, Medipol University, Istanbul, 34303, Turkey
- Subjects
Sorafenib ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Neovascularization ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Fibrosis ,medicine ,Osteopontin ,biology ,business.industry ,Vascular Endothelial Growth Factor ,Laminectomy ,General Medicine ,Basic Study ,medicine.disease ,Staining ,Vascular endothelial growth factor ,CD105 ,Spinal Epidural Fibrosis ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Immunohistochemistry ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Adilay, Hüseyin Utku (Balikesir Author), AIM To determine if sorafenib, an antineoplastic agent, could prevent the development of spinal epidural fibrosis (EF). METHODS The study used CD105 and osteopontin antibodies in an immunohistochemical approach to quantify EF that occurred as a consequence of laminectomy in rats. Wistar albino rats (n = 16) were divided into two groups: control (L1-2 level laminectomy only) and sorafenib treatment (L1-2 level laminectomy + topical sorafenib). The animals were euthanatized after 6 wk, and the EF tissues were examined for histopathological changes after immunohistochemical staining. The EF grades were assigned to the tissues, and the treatment and control groups were compared. RESULTS The EF thickness, inflammatory cell density, and arachnoid adherences determined by light microscopy were significantly higher in the control group compared to the sorafenib-treated group. Based on fibrosis scores, the extent of EF in the treatment group was significantly lower than in the controls. Immunohistochemical staining for CD105 to identify microvessels revealed that the EF grades based on vessel count were significantly lower in the treatment group. Staining for osteopontin did not show any significant differences between the groups in terms of the extent of EF. The staging of EF based on vascular counts observed after immunohistochemical staining for CD105, but not for osteopontin, was compatible with conventional staging methods. Neither toxic effects on tissues nor systemic side effects were observed with the use of sorafenib. CONCLUSION Local administration of sorafenib significantly reduced post-laminectomy EF. Decreased neovascularization in spinal tissue may be due to the sorafenib-induced inhibition of vascular endothelial growth factor.
- Published
- 2018
- Full Text
- View/download PDF